Q
Qingyuan Zhang
Researcher at Harbin Medical University
Publications - 22
Citations - 766
Qingyuan Zhang is an academic researcher from Harbin Medical University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 10, co-authored 22 publications receiving 450 citations.
Papers
More filters
Journal ArticleDOI
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Xichun Hu,Jian Zhang,Binghe Xu,Zefei Jiang,Joseph Ragaz,Zhongsheng Tong,Qingyuan Zhang,Xiaojia Wang,Ji-feng Feng,Dan-mei Pang,Minhao Fan,Jin Li,Biyun Wang,Zhonghua Wang,Qunling Zhang,Si Sun,Chun-mei Liao +16 more
TL;DR: The results indicate that apatinib dose of 500 mg rather than 750 mg is the recommended starting dose for the heavily pretreated mTNBC patients with measurable rate of partial response and PFS.
Journal ArticleDOI
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma.
Yuqin Song,Jianqiu Wu,Xinchuan Chen,T. Lin,Junning Cao,Yan-Yan Liu,Yaozhong Zhao,Jie Jin,Haiwen Huang,Jianda Hu,Jun Luo,Liling Zhang,Hongwei Xue,Qingyuan Zhang,Weiwei Wang,Chun Xia Chen,Jifeng Feng,Jun Zhu +17 more
TL;DR: Camrelizumab demonstrated a high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.
Journal ArticleDOI
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Grzegorz S. Nowakowski,Annalisa Chiappella,Randy D. Gascoyne,David Scott,Qingyuan Zhang,Wojciech Jurczak,Muhit Ozcan,Xiaonan Hong,Jun Zhu,Jie Jin,David Belada,Juan Bergua,Francesco Piazza,Heidi Mocikova,Anna Lia Molinari,Dok Hyun Yoon,Federica Cavallo,Monica Tani,Kazuhito Yamamoto,Koji Izutsu,Koji Kato,Myron S. Czuczman,Sarah Hersey,Adrian Kilcoyne,Jacqueline Russo,Krista Hudak,Jingshan Zhang,Steve Wade,Thomas E. Witzig,Umberto Vitolo +29 more
TL;DR: In this paper, the activated B-cell-like (ABC) subtype of diffuse large b-cell lymphoma (DLBCL) showed inferior survival with standard rituximab plus cyclophosphamide, doxorubici...
Journal ArticleDOI
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
Umberto Vitolo,T. E. Witzig,Randy D. Gascoyne,David Scott,Qingyuan Zhang,Wojciech Jurczak,Muhit Ozcan,Xiaonan Hong,Jun Zhu,Jie Jin,David Belada,J.M. Bergua,Francesco Piazza,Heidi Mocikova,A. L. Molinari,Dok Hyun Yoon,Federica Cavallo,Monica Tani,Koji Izutsu,Kouji Kato,Myron S. Czuczman,Sarah Hersey,A. Kilcoyne,Jacqueline Russo,Krista Hudak,Jingshan Zhang,Annalisa Chiappella,G.S. Nowakowski +27 more
TL;DR: DLBCL patients with mutations in relapse-enriched genes, specifically hotspot deletions, may have power as biomarkers to identify patients at a high risk of relapse and could inform on the mechanism of acquired resistance to components of R-CHOP.
Journal ArticleDOI
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Lin Shen,Jun Guo,Qingyuan Zhang,Hongming Pan,Ying Yuan,Yuxian Bai,Tianshu Liu,Qing Zhou,Jun Zhao,Yongqian Shu,Xiaoming Huang,Siyang Wang,Jie Wang,Ai-Ping Zhou,Dingwei Ye,Ting Sun,Yujuan Gao,Silu Yang,Zoubai Wang,Jian Li,Yi-Long Wu +20 more
TL;DR: Tislelizumab was generally well tolerated among Chinese patients andAntitumor activity was observed in patients with multiple solid tumors, including nasopharyngeal carcinoma cohort.